EirGenix Inc. has entered into a second global exclusive licensing agreement with biosimilar leader Sandoz AG for the commercialization of EG1206A, a pertuzumab biosimilar targeting HER2-positive breast cancer. The deal, announced November 12, 2025, covers all territories except Taiwan, Mainland China, Macau, South Korea, Mongolia, Brunei, Cambodia, Indonesia, Laos, Myanmar, the Philippines, and Japan.
Under the agreement terms, EirGenix will receive up to $152 million in upfront and milestone payments, plus profit sharing once the product launches in licensed territories and potential sales incentives based on market performance. EirGenix retains responsibility for product development, manufacturing, and supply.
Regulatory Progress and Development Pathway
EG1206A has completed its pharmacokinetic clinical study and received positive feedback from both the U.S. FDA and European Medicines Agency last month. The regulatory agencies confirmed that the biosimilar qualifies for an abbreviated development pathway, allowing for the waiver of Phase III comparative efficacy trials.
This regulatory milestone represents a significant advancement in the product's development timeline and reduces the traditional clinical development burden typically required for biosimilar approval.
Market Opportunity and Clinical Context
The agreement targets a substantial patient population, with approximately 2.3 million breast cancer patients globally, of which about 20% are diagnosed with HER2-positive disease. The combination therapy of trastuzumab and pertuzumab has become the current standard of care for these patients.
Recent studies suggest that pertuzumab combined with trastuzumab deruxtecan (Enhertu®) may become the new first-line treatment for HER2-positive metastatic breast cancer, indicating strong potential for future market expansion of EG1206A. According to Roche's 2024 annual report, global sales of the reference product Perjeta® reached CHF 3.62 billion (approximately $4 billion).
Strengthened Partnership
This licensing agreement builds upon the existing collaboration between Sandoz and EirGenix. The companies previously signed a global commercialization agreement for EG12014, a trastuzumab biosimilar available in both 150 mg and 420 mg formulations. EG12014 has already received approval from the European Commission and is currently under Biologics License Application review by the U.S. FDA.
The launch of second-generation EG1206A alongside the first-generation EG12014 will enhance treatment options for patients with HER2-positive breast cancer, providing a comprehensive biosimilar portfolio for this patient population.
Company Positioning and Future Outlook
EirGenix has successfully utilized reverse engineering technologies to develop multiple biosimilar products, with this agreement underscoring the company's global competitiveness and technical excellence. The company is accelerating development of four HER2-targeted antibody programs, expanding both its in-house product pipeline and contract development and manufacturing organization services.
The increased utilization of EirGenix's two commercial production lines in Zhubei demonstrates the company's rapid progress in scaling manufacturing capabilities. As global demand for biosimilar research and development continues to grow, EirGenix's technical expertise, production capacity, and large-scale facilities have attracted attention from international pharmaceutical companies.
Sandoz, headquartered in Basel, Switzerland, recorded net sales of $10.4 billion in 2024 and maintains a portfolio of approximately 1,300 products addressing diseases from common conditions to cancer. The company provides 900 million patient treatments globally through its network of more than 20,000 employees across 100 nationalities.
